News | PET Imaging | August 06, 2021

New Imaging Isotope Meets Promising Therapy Isotopes

New production methods for cerium-134 advance technologies for imaging human disease and guiding treatment.

Cerium-134 can be targeted to provide an imaging analogue for two different therapy isotopes, actinium-225 and thorium-227. This helps scientists understand these therapy isotopes and develop new treatments. Image courtesy of Donald Montoya, Los Alamos National Laboratory

Cerium-134 can be targeted to provide an imaging analogue for two different therapy isotopes, actinium-225 and thorium-227. This helps scientists understand these therapy isotopes and develop new treatments. Image courtesy of Donald Montoya, Los Alamos National Laboratory

August 6, 2021 — A multidisciplinary team has demonstrated the production, purification, and potential application of cerium-134. This isotope decays into lanthanum-134, an isotope useful for positron emission tomography (PET) imaging. PET imaging uses radioactive substances to visualize and measure processes in the body. It is an essential tool in diagnosing disease and monitoring treatment. The team demonstrated the use of cerium-134 for PET imaging in mice. The results show that cerium-134, through its lanthanum-134 decay product, could serve as a diagnostic partner for medical treatments based on actinium-225 or thorium-227.

Increasing the availability of cerium-134 for imaging could benefit the medical use of therapeutic radioactive isotopes. These isotopes emit alpha particles that target cancer and other diseases. Cerium-134 is chemically similar to actinium-225 and thorium-227. This means cerium-134 can be attached to the same targeting systems as the therapeutic isotopes. Using the same targeting systems means that cerium-134 diagnostics and actinium-225 and thorium-227 treatments will behave in similar ways in the body. This allows scientists to use cerium-134 to view and monitor actinium-225 and thorium-227 as they work. The result is more information for medical researchers and clinicians treating disease.

Developing targeted medical interventions that use radioactive isotopes to treat disease could transform how science treats disease. This approach involves selectively delivering an alpha-emitting radioisotope like actinium-225 and thorium-227 to diseased cells such as tumors. The radioactive decay kills the diseased cell while sparing the surrounding healthy tissue. Widespread implementation of this approach would be easier if medical practitioners had more tools to non-invasively and accurately track the radioactive medication in the body. One such tool is PET imaging with cerium-134. Unfortunately, actinium-225, thorium-227, and many other alpha-emitting radioisotopes are incompatible with PET imaging. The team demonstrated in mice that PET imaging cerium-134, through its lanthanum-134 decay product, can track actinium-225 and thorium-227. Greater availability of cerium-134 therefore opens the door to the development of additional targeted cancer therapies.

For more information: www.isotopes.gov

Related Content

Strategies to help guide nuclear radiology teams at various healthcare systems in 2021 and beyond
Feature | Nuclear Imaging | September 16, 2021 | By Staff of the American Society of Nuclear Cardiology (ASNC)
A year after COVID-19 turned the world upside do
Evaluation of therapeutic efficacy of drug candidates in preclinical oncology with positron emission tomography (PET)

Getty Images

Feature | PET Imaging | September 14, 2021 | By Todd Sasser, Ph.D.
Plan to attend RSNA21 at McCormick Place Chicago, Nov. 28 – Dec. 2, 2021

Getty Images

News | RSNA | September 13, 2021
September 13, 2021 — The Radiological Society of North America (RSNA) today announced highlights of the Technical Exh
Comment letters on the 2022 physician fee schedule and Radiation Oncology Model urge CMS to scale back extreme cuts that jeopardize access to life-saving cancer treatments

Getty Images

News | ASTRO | September 09, 2021
September 9, 2021 — The American Society for Radiation Oncology (AS...

Image of a STING protein, courtesy of UCLA Jonsson Comprehensive Cancer Center

News | PET Imaging | September 08, 2021
September 8, 2021 — A new study from scientists at the UCLA Jonsso...
Gallium-68 from GalliaPharm is used for the preparation of diagnostic imaging drugs in Positron Emission Tomography (PET).
News | PET Imaging | September 03, 2021
September 3, 2021 — Eckert & Ziegler Radiopharma GmbH has successfully submitted an amendment to their Drug Maste
RaySearch Laboratories AB (publ) will be showcasing the latest oncology software innovations at ESTRO 2021, to be held in Madrid Aug. 27-30. Attendees will be able to book demonstrations of the RayStation treatment planning system, RayIntelligence the cloud-based oncology analytics system, and RayCare the oncology information system during the congress.
News | Radiation Oncology | August 30, 2021
August 30, 2021 — RaySearch Laboratories AB (publ) will be showcasing the latest oncology software innovations at ...